GPR40 Receptor Agonists for the Treatment of Type 2 Diabetes and Related Diseases.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab, LLC., 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2018 Aug 13;9(9):870-871. doi: 10.1021/acsmedchemlett.8b00343. eCollection 2018 Sep 13.
Abstract
摘要
相似文献
1
GPR40 Receptor Agonists for the Treatment of Type 2 Diabetes and Related Diseases.用于治疗2型糖尿病及相关疾病的GPR40受体激动剂
ACS Med Chem Lett. 2018 Aug 13;9(9):870-871. doi: 10.1021/acsmedchemlett.8b00343. eCollection 2018 Sep 13.
2
Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.新型 GPR40 激动剂的慢性治疗基于葡萄糖依赖性胰岛素分泌来改善全身葡萄糖代谢。
J Pharmacol Exp Ther. 2013 Sep;346(3):443-52. doi: 10.1124/jpet.113.206466. Epub 2013 Jul 12.
3
Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.新型 G 蛋白偶联受体 40 激动剂 DS-1558 与胰高血糖素样肽-1 受体激动剂联合增强胰岛素分泌和改善葡萄糖耐量。
Eur J Pharmacol. 2014 Aug 15;737:194-201. doi: 10.1016/j.ejphar.2014.05.014. Epub 2014 May 22.
4
Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).游离脂肪酸受体 1（FFA1R 或 GPR40）激动剂作用的结构基础。
Chem Biol Drug Des. 2018 Mar;91(3):668-680. doi: 10.1111/cbdd.13131. Epub 2017 Nov 16.
5
GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.用于治疗2型糖尿病的GPR40激动剂：生物学特性与化学空间
Bioorg Med Chem Lett. 2016 Dec 1;26(23):5603-5612. doi: 10.1016/j.bmcl.2016.10.074. Epub 2016 Oct 26.
6
GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo.GPR40（FFAR1）- 在体外结合 Gs 和 Gq 信号传导与体外和体内强大的肠促胰岛素分泌作用相关。
Mol Metab. 2014 Oct 24;4(1):3-14. doi: 10.1016/j.molmet.2014.10.002. eCollection 2015 Jan.
7
Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.G蛋白偶联受体40（GPR40/FFA1/FFAR1）小分子调节剂的发现与开发进展：2型糖尿病的一个新兴靶点
Expert Opin Ther Pat. 2009 Feb;19(2):237-64. doi: 10.1517/13543770802665717.
8
Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.基于噻吩-2-基丙酸骨架的强效且口服生物可利用的GPR40完全激动剂的发现。
J Med Chem. 2017 Apr 13;60(7):2697-2717. doi: 10.1021/acs.jmedchem.6b01357. Epub 2017 Mar 17.
9
Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.GPR40调节剂（FFA1/FFAR1）开发的最新进展：2型糖尿病的新兴靶点
Mini Rev Med Chem. 2017;17(11):947-958. doi: 10.2174/1389557517666170120152917.
10
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.GPR40 激动剂治疗 2 型糖尿病：“TAKing”一击后的生活。
Diabetes Obes Metab. 2015 Jul;17(7):622-9. doi: 10.1111/dom.12442. Epub 2015 Feb 24.
引用本文的文献
1
Renal Protection of HWL-088and ZLY-032, Two Dual GPR40/PPARδ Agonists, in Adenine-Induced Renal Fibrosis Model.两种双重GPR40/PPARδ激动剂HWL-088和ZLY-032在腺嘌呤诱导的肾纤维化模型中的肾脏保护作用
Chem Biodivers. 2025 Feb;22(2):e202401598. doi: 10.1002/cbdv.202401598. Epub 2024 Nov 8.
2
From Functional Fatty Acids to Potent and Selective Natural-Product-Inspired Mimetics via Conformational Profiling.从功能性脂肪酸到通过构象分析获得的强效且具选择性的天然产物启发的模拟物。
ACS Cent Sci. 2024 Feb 12;10(2):477-486. doi: 10.1021/acscentsci.3c01155. eCollection 2024 Feb 28.
3
Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases.代谢物 G 蛋白偶联受体在心脏代谢疾病中的作用。
Cells. 2021 Nov 29;10(12):3347. doi: 10.3390/cells10123347.
4
Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release.基于药效团的贝特类药物和维 A 酸类药物的再利用：作为 GPR40 变构配体对胰岛素释放有活性。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):377-383. doi: 10.1080/14756366.2020.1864629.
5
Metabolism of fatty acids and bile acids in plasma is associated with overactive bladder in males: potential biomarkers and targets for novel treatments in a metabolomics analysis.在代谢组学分析中，男性中脂肪酸和胆汁酸在血浆中的代谢与膀胱过度活动症有关：潜在的生物标志物和新疗法的靶点。
Int Urol Nephrol. 2020 Feb;52(2):233-238. doi: 10.1007/s11255-019-02299-8. Epub 2019 Oct 5.
6
Anti-Apoptotic Effect of G-Protein-Coupled Receptor 40 Activation on Tumor Necrosis Factor-α-Induced Injury of Rat Proximal Tubular Cells.G 蛋白偶联受体 40 激活对肿瘤坏死因子-α诱导的大鼠近端肾小管细胞损伤的抗凋亡作用。
Int J Mol Sci. 2019 Jul 10;20(14):3386. doi: 10.3390/ijms20143386.
本文引用的文献
1
Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).游离脂肪酸受体 1（FFA1R 或 GPR40）激动剂作用的结构基础。
Chem Biol Drug Des. 2018 Mar;91(3):668-680. doi: 10.1111/cbdd.13131. Epub 2017 Nov 16.
2
β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.β 细胞信号转导与胰岛素促泌剂：改善糖尿病治疗的途径。
Diabetes Obes Metab. 2017 Sep;19 Suppl 1:22-29. doi: 10.1111/dom.12995.
3
GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.用于治疗2型糖尿病的GPR40激动剂：生物学特性与化学空间
Bioorg Med Chem Lett. 2016 Dec 1;26(23):5603-5612. doi: 10.1016/j.bmcl.2016.10.074. Epub 2016 Oct 26.
4
GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.用于治疗2型糖尿病的GPR40激动剂：益处与挑战
Curr Drug Targets. 2016;17(11):1292-300. doi: 10.2174/1389450117666151209122702.
Zotero 插件